Surgeon General's Workshop on Deep Vein Thrombosis
Oral Anticoagulant Therapy and Its Limitations
1 | 2 | 3 | 4 | 5 | 6
| 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18
Return to Menu
SLIDE 1: Oral Anticoagulant Therapy and Its
Limitations The Importance of Expert Management
Oral Anticoagulant Therapy and Its Limitations The Importance of Expert
Management
Jack Ansell, M.D.
Boston University School of Medicine
May
2006
Return to Top
SLIDE 2: Warfarin, 20th Most Prescribed Drug in the
US
|
Hydrocodone w/APAP 92,720
Lipitor 69,766
Lisinopril 46,207
Atenolol 44,162
Synthroid 44,056
Amoxicillin 41,394
Hydrochlorothiazide 41,346
Zithromax 37,172
Furosemide 36,508
Norvasc 34,729
Toprol XL 32,795
Alprazolam 32,405
Albuterol 31,220 |
Zoloft 29,878
Zocor 27,234
Metformin HCL 25,473
Ibuprofen 25,188
Triamterene w/HCTZ 24,616
Ambien 24,494
Warfarin 24,290
Cephalexin 23,665
Nexium 23,642
Prevacid 23,629
Lexapro 22,597
Prednisone 22,507 |
23.5 million scripts in 2000
2004 data from
www.rxlist.com/top200.htm
Return to Top
SLIDE 3: Indications for Warfarin Therapy
- Prophylaxis and/or treatment of venous thrombosis and its extension,
and pulmonary embolism.
- Prophylaxis and/or treatment of the thromboembolic complications
associated with atrial fibrillation and/or cardiac valve replacement.
- To reduced the risk of death, recurrent myocardial infarction, and
thromboembolic events such as stroke or systemic embolization after myocardial
infarction.
Return to Top
SLIDE 4: Coagulation Cascade Vitamin K Dependent
Factors
Graphic of Coagulation Cascade Vitamin K Dependent Factors:
Within the coagulation cascade, there are 4 coagulation factors that require vitamin K for their normal synthesis: factors II, VII, IX, and X. When vitamin K is absent (or interfered with by warfarin therapy), these normal functioning factors are degraded based on their normal metabolic half-lives (half-life in hours indicated next to the respective factor).
Return to Top
SLIDE 5: No title
Graphic: Warfarin Pharmacology
The only oral anticoagulants available for clinical use are the coumarin and indandedione derivatives, collectively referred to as the vitamin K antagonists (VKA), since their mechanism of action is to interfere with vitamin K which is necessary for the synthesis of specific coagulation proteins (factors II, VII, IX, and X).
Return to Top
SLIDE 6: Drawbacks to Warfarin Therapy
- Delayed onset and offset of action.
- Frequent blood test monitoring required:
- the dose response is unpredictable,
- has a narrow therapeutic range above which or below which
bleeding or thromboembolism can occur, and
- multiple factors (illness, drugs, diet, etc.) influence dose
response.
- Monitoring assay has serious limitations.
- Reversibility of anticoagulant affect is slow.
- Requires labor-intensive follow up, expert dose management, and
frequent patient communication.
Return to Top
SLIDE 7: No title
Graphic: Warfarin Pharmacology
Recent new developments in warfarin pharmacology have uncovered major reasons for individual responses to therapy. These include mutations in the gene that codes for the major enzyme that metabolizes warfarin (called CYP2C9) and mutations in the gene that codes for the enzyme that is the target of warfarin's effect (called the vitamin K oxide reductase complex 1 or VKORC1)
Return to Top
SLIDE 8: Mutations in the CYP2C9 Gene Leading to
Impaired Metabolism
Two common CYP2C9 SNPs are associated with impaired metabolism of
S-warfarin:
- A SNP in exon 3 (C (right arrow) T) is denoted CYP2C9*2
- A SNP in exon 7 (A (right arrow) C) is denoted CYP2C9*3
(The
wild type enzyme is denoted CYP2C9*1)
Both of these point mutations are associated with reduced warfarin
requirements needed to achieve and maintain a therapeutic INR
Return to Top
SLIDE 9: CYP2C9 Gene Variants & AC Outcomes
| Genotype |
Exp / Actual Prevalence |
Mean Dose |
Maj / Fatal Bleeds |
| 1/1 (127) |
65.7 / 68.6 |
5.6 MG |
5.6 % |
| 1/*2 (28) |
17.1 / 15.1 |
4.9 |
9.4 % |
| 1/*3 (18) |
13.6 / 9.7 |
3.3 |
12.5 % |
| *2/*2 (4) |
1.1 / 2.2 |
4.0 |
22.2 % |
| *2/*3 (3) |
1.8 / 1.6 |
2.3 |
100 % |
| *3/*3 (5) |
0.7 / 2.7 |
1.6 |
13.3 % |
Gene variant group also required more time to achieve stable dose and
had increased risk of high INR
Return to Top
SLIDE 10: No title
Graphic: Warfarin Pharmacology
Recent new developments in warfarin pharmacology have uncovered major reasons for individual responses to therapy. These include mutations in the gene that codes for the major enzyme that metabolizes warfarin (called CYP2C9) and mutations in the gene that codes for the enzyme that is the target of warfarin's effect (called the vitamin K oxide reductase complex 1 or VKORC1)
Return to Top
SLIDE 11: VKORC1 Haplotype Frequency & Effect on
Warfarin Dose Maintenance
| Haplotype |
# Patients (Freq) |
Ave Maintenance Dose (Homozygous) |
| H1 |
43 (12%) |
2.9 (2.2-3.7) |
| H2 |
88 (24%) |
3.0 (2.5-3.6) |
| H7 |
132 (35%) |
6.0 (5.2-6.9) |
| H8 |
28 (8%) |
4.8 (3.4-6.7) |
| H9 |
77 (21%) |
5.5 (4.5-6.7) |
Return to Top
SLIDE 12: Genetic Polymorphisms and Warfarin
Therapy
| |
CYP2C9
Polymorphisms |
|
|
CYP2C9*1 |
CYP2C9*2 |
CYP2C9*3 |
|
Caucasians |
79% - 89% |
8% - 19% |
6% - 10% |
|
Native Canadians |
91% |
3% |
6% |
|
African Americans |
98% |
1.5% - 3.6% 0.05% - 1.5% |
|
|
Asians |
95% - 98% |
0% |
1.7% - 5% |
| |
VKORC1 Haplotypes |
|
|
H1H2 |
H8H9 |
|
Euro Americans |
37% |
58% |
|
African Americans |
14% |
49% |
|
Asian American |
89% |
10% |
Return to Top
SLIDE 13: High Quality Dose Management (ie, staying
within therapeutic range)
The best outcomes with warfarin therapy are achieved by knowing . . .
- When to use (proper indications)
- What intensity to use (proper therapeutic range)
- How to use (proper dose management)
Proper dose management requires . . .
- Dosing decisions and management of nontherapeutic INRs
- Peri-procedural dose management
- Follow-up & communication - Education
Return to Top
SLIDE 14: Models of Anticoagulation
Management
- Routine Medical Care (Usual Care)
- Anticoagulation Clinic (ACC)
- Patient Self-Testing (PST)
- Patient Self-Management (PSM
Return to Top
SLIDE 15: Frequency of Hemorrhage & TE with
Usual Care vs ACC
|
Study |
Pat Yrs |
Major Hem |
Rec TE |
|
7 UC Studies |
3,062 |
5.5% |
2.7% |
|
8 ACC Studies |
17,644 |
2.5% |
1.6% |
Return to Top
SLIDE 16: No title
Four photos of blood testing devices.
Return to Top
SLIDE 17: PST & PSM vs UC or ACC
|
Study |
Comparators |
TTR |
Hem & TE |
|
1 Study |
PSTACC vs UC |
56% vs 32% |
14% vs 25% |
|
3 Studies |
PSTACC vs ACC |
73% vs 67% |
no AEs |
|
5 Studies |
PSM vs UC |
75% vs 54% |
3.2% vs 6.1% |
|
5 Studies |
PSM vs ACC |
72% vs 64% |
1.4% vs 1.0% |
Return to Top
SLIDE 18: High Quality Dose Management (ie, staying
within therapeutic range)
The best outcomes with warfarin therapy are achieved by knowing . .
.
- When to use (proper indications)
- What intensity to use (proper therapeutic range)
Proper dose management requires . . .
- Dosing decisions and management of nontherapeutic INRs
- Peri-procedural dose management
- Follow-up & communication
- Education
Return to Top
Return to Top
Return to Menu
|
